- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.02. | GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight' | ||
| 04.02. | Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1 | ||
| 03.02. | HHS launches $100M antiviral prize to develop broad-spectrum therapies | ||
| 03.02. | Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed | ||
| 03.02. | Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges | ||
| 03.02. | Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b | ||
| 03.02. | NMD flunks rare disease trial, but flexes secondary data to accelerate program | ||
| 02.02. | Novo's CagriSema tops semaglutide in ph. 3 diabetes study | ||
| 02.02. | GSK plans to lay off up to 350 R&D workers across US, UK | ||
| 02.02. | GSK gives back rights to Wave's genetic disease RNA editor | ||
| 02.02. | Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again | ||
| 02.02. | China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug | ||
| 02.02. | Skye links CB1-Wegovy combo to 22.3% weight loss after a year in extension of failed ph. 2 study | ||
| 02.02. | Roche's return to RNA continues with $1.7B deal for Sanegene program | ||
| 02.02. | Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease | ||
| 30.01. | Corcept submitted lead asset for approval despite FDA flagging risk of 'significant review issues' | ||
| 30.01. | Moderna's latest CMO steps down after barely a year | ||
| 30.01. | Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech | ||
| 30.01. | Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program | ||
| 30.01. | AstraZeneca returns to China's CSPC Pharma for $4.7B obesity deal | ||
| 30.01. | Moderna offloads late-stage rare disease drug to Recordati for $50M upfront | ||
| 29.01. | Formation Bio's China shopping spree continues with $500M biobucks autoimmune pact | ||
| 29.01. | Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine | ||
| 29.01. | Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials | ||
| 29.01. | Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.